

## **MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab (L+R) in patients with relapsed or refractory (R/R) follicular or marginal zone lymphoma (FL or MZL)**

Loretta J. Nastoupil<sup>1</sup>, Yuqin Song<sup>2</sup>, Laurie Sehn<sup>3</sup>, Clémentine Sarkozy<sup>4</sup>, Pier Luigi Zinzani<sup>5</sup>, Antonio Salar<sup>6</sup>, Jun Zhang<sup>7</sup>, Sha Huang<sup>7</sup>, Julie Wang<sup>7</sup>, Richard Delarue<sup>8</sup>, Judith Trotman<sup>9</sup>

<sup>1</sup>MD Anderson Cancer Center, Houston, TX, USA; <sup>2</sup>Peking University Cancer Hospital and Institute, Beijing, China; <sup>3</sup>University of British Columbia, Vancouver, BC, Canada; <sup>4</sup>Institut Curie, Saint Cloud, Paris, France; <sup>5</sup>University of Bologna, Bologna, Italy; <sup>6</sup>Hospital del Mar, Barcelona, Spain; <sup>7</sup>BeiGene (Shanghai) Co., Ltd. Shanghai, China; BeiGene USA, Inc., San Mateo, CA, USA; <sup>8</sup>BeiGene Switzerland GmbH, Basel, Switzerland; <sup>9</sup>Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia

**Introduction:** Bruton tyrosine kinase inhibitors (BTKis) have emerged as a treatment strategy for patients with B-cell malignancies, including indolent non-Hodgkin lymphomas. Zanubrutinib, a potent and specific second-generation BTKi, has demonstrated improved efficacy and tolerability over first-generation BTKis in several diseases, including chronic lymphocytic leukemia/small lymphocytic lymphoma and Waldenström macroglobulinemia. Zanubrutinib is approved in >15 countries, including the US and countries in the EU, for patients with R/R MZL who received ≥1 anti-CD20–based regimen, based on the single-arm MAGNOLIA trial. In ROSEWOOD, a phase 2 randomized study in R/R FL, zanubrutinib plus obinutuzumab (Z+O) had superior efficacy vs obinutuzumab alone and a favorable safety profile.

**Trial Design:** MAHOGANY (BGB-3111-308; NCT05100862), a randomized, open-label phase 3 trial, will compare the efficacy and safety of zanubrutinib plus an anti-CD20 monoclonal antibody vs L+R in 2 independent cohorts of patients with R/R FL or MZL. Key eligibility criteria include histologically confirmed FL (grades 1-3A) or MZL, ≥1 prior anti-CD20–based regimen, disease that relapsed after or is refractory to the most recent systemic therapy, need for treatment, naivety to BTKi treatment, and no prior resistance to a lenalidomide-based regimen. In the FL cohort, 600 patients will be randomized 1:1 to Z+O or L+R. In the MZL cohort, 150 patients will be randomized 1:1 to zanubrutinib plus rituximab or L+R. Randomization for both cohorts is stratified by age (≥60 vs <60 years) and number of prior lines of therapy (1-2 vs >2), with the FL cohort also stratified by rituximab-refractory status (yes vs no). The primary endpoint in both cohorts is progression-free survival as assessed by an independent review committee (IRC), according to Lugano 2014 criteria. Key secondary endpoints are ORR by IRC assessment (both cohorts) and overall survival (FL cohort). Zanubrutinib is given at 160 mg twice daily or 320 mg once daily, according to investigator, until progression or unacceptable toxicity. Obinutuzumab or rituximab is given for up to 8 infusions. Lenalidomide is given following the approved label for up to 12 cycles. Recruitment is ongoing.